243 related articles for article (PubMed ID: 22068162)
1. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.
Frampton G; Invernizzi P; Bernuzzi F; Pae HY; Quinn M; Horvat D; Galindo C; Huang L; McMillin M; Cooper B; Rimassa L; DeMorrow S
Gut; 2012 Feb; 61(2):268-77. PubMed ID: 22068162
[TBL] [Abstract][Full Text] [Related]
2. Progranulin and cholangiocarcinoma: another bad boy on the block!
Alvaro D
Gut; 2012 Feb; 61(2):170-1. PubMed ID: 22068170
[No Abstract] [Full Text] [Related]
3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Francis H; DeMorrow S; Venter J; Onori P; White M; Gaudio E; Francis T; Greene JF; Tran S; Meininger CJ; Alpini G
Gut; 2012 May; 61(5):753-64. PubMed ID: 21873469
[TBL] [Abstract][Full Text] [Related]
5. The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1.
Frampton G; Ueno Y; Quinn M; McMillin M; Pae HY; Galindo C; Leyva-Illades D; DeMorrow S
Am J Physiol Gastrointest Liver Physiol; 2012 Dec; 303(11):G1202-11. PubMed ID: 23086914
[TBL] [Abstract][Full Text] [Related]
6. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes.
Meng F; Yamagiwa Y; Ueno Y; Patel T
J Hepatol; 2006 Jun; 44(6):1055-65. PubMed ID: 16469407
[TBL] [Abstract][Full Text] [Related]
8. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
9. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
11. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
Francis H; Onori P; Gaudio E; Franchitto A; DeMorrow S; Venter J; Kopriva S; Carpino G; Mancinelli R; White M; Meng F; Vetuschi A; Sferra R; Alpini G
Mol Cancer Res; 2009 Oct; 7(10):1704-13. PubMed ID: 19825989
[TBL] [Abstract][Full Text] [Related]
12. Leptin enhances cholangiocarcinoma cell growth.
Fava G; Alpini G; Rychlicki C; Saccomanno S; DeMorrow S; Trozzi L; Candelaresi C; Venter J; Di Sario A; Marzioni M; Bearzi I; Glaser S; Alvaro D; Marucci L; Francis H; Svegliati-Baroni G; Benedetti A
Cancer Res; 2008 Aug; 68(16):6752-61. PubMed ID: 18701500
[TBL] [Abstract][Full Text] [Related]
13. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.
Alpini G; Invernizzi P; Gaudio E; Venter J; Kopriva S; Bernuzzi F; Onori P; Franchitto A; Coufal M; Frampton G; Alvaro D; Lee SP; Marzioni M; Benedetti A; DeMorrow S
Cancer Res; 2008 Nov; 68(22):9184-93. PubMed ID: 19010890
[TBL] [Abstract][Full Text] [Related]
14. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma.
Coufal M; Invernizzi P; Gaudio E; Bernuzzi F; Frampton GA; Onori P; Franchitto A; Carpino G; Ramirez JC; Alvaro D; Marzioni M; Battisti G; Benedetti A; DeMorrow S
Int J Cancer; 2010 May; 126(9):2112-22. PubMed ID: 19795457
[TBL] [Abstract][Full Text] [Related]
15. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
17. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
18. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
19. NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.
Ge X; Wang Y; Wang Y; Li Q; Yu H; Miao L
Dig Dis Sci; 2013 Jun; 58(6):1636-43. PubMed ID: 23314853
[TBL] [Abstract][Full Text] [Related]
20. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
